Johnson & Johnson (LTS:0R34) FFO


LTS:0R34 Johnson & Johnson LTS:0R34
89 GF Score
Price $253.42
GF Value $189.64
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0R34
89GF Score
Johnson & Johnson LTS:0R34
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Johnson & Johnson (LTS:0R34) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of $253.42 is trading 33.6% above its estimated GF Value™ of $189.64. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for LTS:0R34:

  • FFO:
  • GF Value™: $189.64 vs. price of $253.42 (33.6% above fair value)
  • GF Score™: 89/100 with 7 warning signs

No single metric tells the full story. See the LTS:0R34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
89GF Score

Get the complete analysis for LTS:0R34

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$253.42
Price
$189.64
GF Value